Human IgM monoclonal antibodies reactive with HIV-1-infected cells generated using a trans-chromosome mouse

Microbiology and Immunology

Volumn 49, Issue 5, 2005, Pages 447-459

  Okada, Noriko ^a   Yin, Shuping ^a,b   Asai, Suzuka ^a   Kimbara, Noriaki ^a   Dohi, Natsuki ^a   Hosokawa, Masato ^a,c   Wu, Xiaoshan ^a,d   Okada, Hidechika ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d KOBE INSTITUTE OF HEALTH   (Japan)

Author keywords

Apoptosis; Complement; HIV; Human monoclonal antibody; IgM

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN M ANTIBODY; IMMUNOGLOBULIN MU CHAIN; MONOCLONAL ANTIBODY; TUNICAMYCIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL MEMBRANE; CELLULAR IMMUNITY; CHROMOSOME 14; CHROMOSOME 2; CHROMOSOME 22; CONTROLLED STUDY; CYTOLYSIS; DNA SEQUENCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDOMA CELL CULTURE; MOUSE; MYELOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; SPECIES DIFFERENCE; SPLEEN CELL;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 20444374469     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2005.tb03749.x     Document Type: Article

References (24)

1. Butera, S.T., Roberts, B.D., and Folks, T.M. 1993. Regulation of HIV-1 expression by cytokine networks in CD44-model of chronic infection. J. Immunol. 150: 625-634.
2. Chun, T.W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J.A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T.C., Kou, Y.H., Brookmeyer, R., Zeiger, M.A., Barditch-Crovo, P., and Siliciano, R.F. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183-188.
3. Finzi, D., Hermankova, M., Pierson, T., Carruth, L.M., Buck, C., Chaisson, R.E., Quinn, T.C., Chadwick, K., Margolick, J., Brookmeyer, R., Gallant, J., Markowitz, M., Ho, D.D., Richman, D.D., and Siliciano, R.F. 1997. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy. Science 173: 1295-1300.
4. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119: 493-501.
5. Irie, R.F., Sze, L.L., and Saxton, R.E. 1982. Human antibody to OFA-1, a tumor antigen produced in vitro by Epstein-Barr virus-transformed human B-lymphoid cell lines. Proc. Natl. Acad. Sci. U.S.A. 79: 5666-5670.
6. Ishida, I., Yoshida, H., and Tomizuka, K. 1998. Production of a diverse repertoire of human antibodies in genetically engineered mice. Microbiol. Immunol. 42: 143-150.
7. Kawai, M., He, L., Kawamura, T., Omoto, S., Fujii, Y.R., and Okada, N. 2003. Chimeric human/murine monoclonal IgM antibodies to HIV-1 Nef antigen expressed on chronically infected cells. Microbiol. Immunol. 47: 247-253.
8. Kikukawa, R., Koyanagi, Y., Harada, S., Kobayashi, N., Hatanaka, M., and Yamamoto, N. 1986. Differential susceptibility to the acquired immunodeficiency syndrome retroviruses in clone cells of human leukemic T-cell line MOLT-4. J. Virol. 57: 1159-1162.
9. Lederman, M.M., Purvis, S.F., Walter, E.I., Carey, J.T., and Medof, M.E. 1989. Heightened complement sensitivity of AIDS lymphocytes related to diminished expression of decay-accelerating factor. Proc. Natl. Acad. Sci. U.S.A. 86: 4205-4209.
10. Medof, M.E., Kinoshita, T., and Nussenzweig, V. 1984. Inhibition of complement activation on the surface of cells after incorporation of decay accelerating factor (DAF) into their membranes. J. Exp. Med. 160: 1558-1578.
11. Okada, H., Tanaka, H., and Okada, N. 1983. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes. Eur. J. Immunol. 13: 340-344.
12. Okada, H., Wu, S.X., and Okada, N. 1998. Complement mediated cytolysis and azidothymidine synergistic in HIV-1 suppression. Int. Immunol. 10: 91-95.
13. Okada, N., Harada, R., Fujita, T., and Okada, H. 1989. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int. Immunol. 1: 205-208.
14. Okada, N., Wu, X.S., Mizokami, M., Irie, R.F., and Okada, H. 1999. Human IgM monoclonal antibody to ganglioside GM2 and complement suppress virus propagation in ex vivo cultures of lymphocytes from HIV-1 infected patients. Microbiol. Immunol. 43: 723-737.
15. Okada, N., Wu, X.S., and Okada, H. 1997. Presence of IgM antibodies which sensitize HIV-1-infected cells to cytolysis by homologous complement in long-term survivors of HIV infection. Microbiol. Immunol. 41: 331-336.
16. Perelson, A.S., Essunger, P., Cao, Y., Vesanen, M., Hurley, A., Saksela, K., Markowitz, M., and Ho, D.D. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387: 188-191.
17. Seya, T., Turner, J.R., and Atkinson, J.P. 1986. Purification and characterization of a membrane protein (gp45-70) which is a cofactor for cleavage of C3b and C4b. J. Exp. Med. 163: 837-855.
18. Tomizuka, K., Yoshida, H., Uejima, H., Kugoh, H., Sato, K., Ohguma, A., Hayasaka, M., Hanaoka, K., Oshimura, M., and Ishida, I. 1997. Functional expression and germline transmission of a human chromosome fragment in chimeric mice. Nat. Genet. 16: 133-143.
19. Varambally, S., Bar-Dayan, Y., Bayry, J., Lacroix-Desmazes, S., Horn, M., Sorel, M., Bar-Dayan, Y., Ruberti, G., Kazatchkine, M.D., and Kaveri, S.V. 2004. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int. Immunol. 16: 517-524.
20. Weiss, L., Okada, N., Haeffner-Cavaillon, N., Hattori, T., Faucher, C., Kazatchkine, M.D., and Okada, H. 1992. Decreased expression of the membrane inhibitor of complement-mediated cytolysis CD59 on T lymphocytes of HIV-infected patients. AIDS 6: 379-385.
21. Wu, X., Okada, N., Goto, M., Iwamoto, A., and Okada, H. 2000. The IgM antibody level against ganglioside GM2 correlates to the disease status of HIV-1-infected patients. Microbiol. Immunol. 44: 405-410.
22. Wu, X.S., Okada, N., Iwamori, M., and Okada, H. 1996. IgM natural antibody against an asialo-oligosaccharide, gangliotetraose (Gg4), sensitizes HIV-1 infected cells for cytolysis by homologous complement. Int. Immunol. 8: 153-158.
23. Wu, X.S., Okada, N., Momota, H., Irie, R.F., and Okada, H. 1999. Complement mediated anti-HIV-1 effect induced by human IgM mAb against ganglioside GM2. J. Immunol. 162: 533-539.
24. Yin, S., Okada, N., and Okada, H. 2001. Elimination of latently HIV-1-infected cells by lymphoblasts armed with bifunctional antibody. Microbiol. Immunol. 45: 101-108.